Publications by authors named "J R Lisse"
Introduction: Real-world data on ixekizumab utilization in axial spondyloarthritis (axSpA) are limited. We evaluated ixekizumab treatment patterns and health care resource utilization (HCRU) in patients with axSpA using United States Merative L.P.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the effectiveness of ixekizumab vs. placebo and adalimumab in reducing spinal pain in patients with ankylosing spondylitis (AS) through objective inflammation measures like MRI and CRP levels.!
- In a 52-week trial, ixekizumab showed greater reductions in spinal pain compared to placebo, particularly when inflammation was controlled, and continued to improve at week 52.!
- The analysis suggests that ixekizumab not only helps lessen pain through inflammation reduction but may also work through additional mechanisms, indicating its potential as a more effective treatment for AS pain management.!
Introduction: A new, citrate-free ixekizumab formulation, which is bioequivalent to the original formulation, was associated with significant reduction in injection site pain. This study evaluates patient satisfaction with the first injection experience of citrate-free ixekizumab in a real-world setting.
Methods: A non-interventional, observational, web-based survey of adults (≥ 18 years) with psoriasis, psoriatic arthritis, or axial spondyloarthritis was conducted between August 2022 and March 2023.
Article Synopsis
- * The research involved analyzing data from patients with simultaneous DIP joint issues and nail psoriasis, measuring treatment outcomes over 52 weeks using the SPIRIT-H2H trial.
- * Results showed that patients treated with IXE experienced significantly better resolution of joint swelling and nail psoriasis compared to those treated with ADA, with improved outcomes observed as early as 12 weeks into treatment.